What is BPC-157 and what is it studied for?

BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. It is studied mainly at the preclinical level — in animals and in vitro — in the context of tissue repair such as tendon, muscle and gastrointestinal mucosa, and for its interaction with nitric oxide and angiogenesis pathways. This is educational information: it is not approved for human use.

What effects does BPC-157 have?

The reported effects — accelerated tissue healing, gastric mucosal protection, promotion of new blood vessels — come almost entirely from rodent and in-vitro studies. There are no completed controlled human trials confirming those effects or establishing safety, so talking about 'effects in people' is premature. This guide is not medical advice.

BPC-157 is classified as research-use-only (RUO) in most jurisdictions and is not approved for human use by the FDA, the EMA or comparable regulators; nor is it authorized as a dietary supplement in the EU. The FDA flagged it in 2023 for safety concerns, and it is on the WADA prohibited list. It is not a licensed medicine.

← Guides

BPC-157: what it is and what is being researched

BPC-157 is one of the peptides that most intrigues people beginning to study the field, and also one of the most surrounded by overstated claims. This guide summarizes, at an educational level, what the molecule is, which mechanisms have been described in the lab, where the evidence really stands and what its legal situation is. It is not medical advice or a recommendation for use, and it contains no doses or protocols: research peptides are not approved for human use in most jurisdictions. If you are looking for information about your own health, consult a healthcare professional.

What BPC-157 is

BPC-157 stands for Body Protection Compound-157. It is a synthetic 15-amino-acid peptide — a pentadecapeptide — whose sequence corresponds to a partial fragment of a protein called BPC, originally isolated from human gastric juice. It is important to understand that BPC-157 as it is studied is a molecule made in a laboratory, not a substance extracted from the body. In its usual research form it is supplied as a lyophilized (dry) powder inside a sealed vial. The campus BPC-157 profile lists its full name, synonyms and reference sequence.

What is studied preclinically

In animal models and in vitro, the main focus has been its possible role in tissue repair: tendon, ligament, muscle, bone and the gastrointestinal mucosa. Mechanistically, preclinical studies attribute much of its effect to modulation of the nitric oxide system (the L-arginine–NO pathway) and to promotion of angiogenesis — the formation of new blood vessels — through VEGFR2 receptor signalling and associated pathways that drive endothelial-cell migration. It is worth stressing that these are mechanistic hypotheses derived from the lab, not effects demonstrated in people.

Where the evidence stands

The BPC-157 literature is almost entirely preclinical: hundreds of rodent and in-vitro studies, the large majority from a single research group. Independent replication is limited, and as of this review (2026) there are no completed, peer-reviewed controlled human efficacy trials. This means promising animal results have not been confirmed in people, and any claim about 'what it does in humans' runs ahead of the evidence. In science, the distance between a result in a mouse and an approved treatment is usually enormous.

Legal and regulatory status

BPC-157 is a research-use-only (RUO) substance in most jurisdictions. It is not approved for human use by the FDA, the EMA or comparable agencies, and it is not authorized as a medicine, dietary supplement or food ingredient in the EU. In 2023 the US FDA placed it in a category of substances presenting significant safety risks for pharmacy compounding. It also appears on the World Anti-Doping Agency (WADA) prohibited list, so its use is banned for athletes subject to anti-doping controls.

Frequently asked questions

What is BPC-157 and what is it studied for?: BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. It is studied mainly at the preclinical level — in animals and in vitro — in the context of tissue repair such as tendon, muscle and gastrointestinal mucosa, and for its interaction with nitric oxide and angiogenesis pathways. This is educational information: it is not approved for human use.
What effects does BPC-157 have?: The reported effects — accelerated tissue healing, gastric mucosal protection, promotion of new blood vessels — come almost entirely from rodent and in-vitro studies. There are no completed controlled human trials confirming those effects or establishing safety, so talking about 'effects in people' is premature. This guide is not medical advice.
Is BPC-157 legal?: BPC-157 is classified as research-use-only (RUO) in most jurisdictions and is not approved for human use by the FDA, the EMA or comparable regulators; nor is it authorized as a dietary supplement in the EU. The FDA flagged it in 2023 for safety concerns, and it is on the WADA prohibited list. It is not a licensed medicine.

This guide is an excerpt of the educational approach of Master of Peptides. The full master's includes the cited encyclopedia, practical tools, exam and certificate.

See the master's →

✓ Last reviewed · 2026-07-22